Drugs / IPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03239496 | Oct 2017 → Nov 2018 | poliomyelitis | Fidec Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03239496 ↗ |
| Modality | Vaccine | “full-dose inactivated polio vaccines (IPV) via intramuscular (IM) administration” NCT03239496 ↗ |
| Route | Intramuscular | “two doses of intramuscular IPV” PMID 33284114 ↗ Oct 2020 |